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Although the prototypical HIV-1 LTR sequences were determined 22 years ago from the initial isolate, elucidat-
ing which transcription factors are critical to replication in vivo, has been difficult. One approach has been to 
examine HIV-1 LTRs that have gone through the gamut of in vivo mutation and selection, in search of absolutely 
conserved sequences. In this vein, RBEIII sequences are virtually 100% conserved in naturally occurring HIV-1 
LTRs. This is because when they are mutated, the MFNLP recreates an RBEIII site. Here, I enumerate some ret-
roviral mutation mechanisms, which could generate the MFNLP. I then review the literature corresponding to 
the MFNLP, highlighting the discovery in 1999, that RBEIII and MFNLP sequences, bind USF and TFII-I coop-
eratively, within the context of earlier and later work that suggests a role in HIV-1 activation, through T-cell re-
ceptor engagement and the MAPK cascade. One exception to the nearly absolute conservation of RBEIII, has 
been a group of long term non progressors (LTNP). These patients harbor deletions to the Nef gene. However, 
the Nef gene overlaps with the LTR, and the LTNP deletions abrogate RBEIII, in the absence of an MFNLP. I 
suggest that the MFNLP retains functional coupling between the MAPK-mediated effects of Nef and the HIV-1 
LTR, through RBEIII. I propose that difficult-to-revert-mutations, to either Nef or RBEIII, result in the conver-
gent LTNP Nef/LTR deletions recently observed. The potential exploitation of this highly conserved pro-
tein-binding site, for chimeric transcription factor repression (CTFR) of HIV-1, functionally striving to emulate 
the LTNP deletions, is further discussed. 
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1.  HIV-1 polymorphisms 
In the 24 years since the discovery of HIV-1 [1], 
with the impetus to cure AIDS, there have been an 
unprecedented number of publications examining 
retroviral polymorphisms. These have led to signifi-
cant advances in understanding mechanisms generat-
ing them. In particular, when a provirus replicates 
along with host cellular DNA during mitosis, progeny 
are extremely homogenous. A case in point is clonal 
expansion of HTLV-1 [2], resulting in small variability 
over centuries [2-5]. This can be attributed to the high 
fidelity of mammalian cellular DNA replication, me-
diated by the 3'-5' exonuclease proofreading activity of 
DNA polymerase [6].   
  When a provirus replicates exogenously by in-
fection, progeny can be extremely heterogeneous [4, 7]. 
Since exogenous retroviral replication involves tran-
scription and reverse transcription, both could con-
tribute towards generating polymorphisms. However, 
RNA polymerase appears to have transcript-assisted 
proofreading activity [8]. Therefore, for exogenously 
replicating retroviruses, such as HIV-1, polymor-
phisms are primarily generated during error prone 
reverse transcription (Fig. 1) [9, 10]. 
 In particular the mis-incorporations produced by 
RNA-templated DNA synthesis and DNA-templated 
DNA synthesis (Fig. 1), have been proven to be exac-
erbated by dNTP imbalances both in vitro and in vivo 
[11-14]. Proof of the existence of these dNTP imbal-
ances in a proportion of retroviral permissive cells [13] 
has provided a mechanistic explanation for observed 
retroviral G to A hypermutations in vivo [11, 13-17]. 
These mis-incorporations result in polymorphisms, 
since reverse transcriptase lacks 3'-to-5' exonuclease 
proof-reading activity [18], provided that the muta-
tions result in replication competent virus that is 
naturally selected in vivo. More recently, RNA editing, 
through APOBEC enzymes, that deaminate cytosine 
to uracil, have also been proposed as a mechanism for 
retroviral G to A hypermutation [19]. In fact, the new-
est role for the HIV-1 Vif protein, is to counter the ef-
fect of APOBEC [20, 21]. Interestingly, Vif may also be 
exploiting the mutation potential afforded by 
APOBEC, in generating more HIV-1 diversity [21], 
rather than simply providing immunity from the in-
nate host APOBEC defense mechanism. 
  Importantly, both templated and non-templated 
miss-incorporations, as well as “slippage”, can occur 
during the jumps of reverse transcription (Fig. 1) [22]. 
Therefore, in addition to point mutations, in vivo Int. J. Biol. Sci. 2007, 3 
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sampled retroviruses also frequently harbor deletions 
and insertions. Here, among the most probable 
mechanistic explanations, in addition to, or in combi-
nation with the above mentioned non-templated addi-
tions, is forced copy-choice strand switching during 
reverse transcription followed by mis-alignment and 
continued polymerization on the new template [23-28]. 
In essence this is a forced emulation of the reverse 
transcription "jumps" depicted in figure 1 [29]. This 
mechanism reconciles the fact that retroviruses can 
synthesize cDNA with only one RNA genomic copy 
[30] whereas viral particles carry 2 copies. The second 
would then serve the failsafe function of providing 
new template to "jump to" when reverse transcriptase 
encounters a nick. In addition, forced copy choice 
strand-switching provides a probable mechanistic ex-
planation for phylogenetic revelations of inter-subtype 
recombinant HIV isolates [15, 31]. The implication is 
that chimeric exogenous retroviruses, containing 
transcribed genomic RNA from two different provi-
ruses, are produced from doubly or multiply infected 
cells. In fact, recombination has now been shown to be 
the primary driving force for generating HIV-1 vari-
ants [32, 33], despite cellular retroviral superinfection 
resistance mechanisms [34]. 
The above retroviral mutation mechanisms high-
light how retroviruses can generate sequence diversity. 
These mechanisms are shared by the larger family of 
elements capable of retro-transposition [7, 35]. How-
ever, HIV-1 undergoes such rapid exogenous viral 
replication and turnover [36-38], that natural selection 
generates enormously heterogeneous populations 
termed quasispecies [16, 39], or swarms, which have 
either temporally adapted to cell-specific microenvi-
ronments, or exist because their specific polymor-
phisms are neutral. 
2.  The MFNLP 
The proviral HIV-1 LTR sequences first investi-
gated, were from the initial isolate [40] and rapidly 
became the prototypical LTR. These sequences or-
chestrate the cellular RNA polymerase II transcription 
machinery, in conjunction with viral proteins, and in-
clude a TATA-box, 3 SP1 sites, 2 NFkB enhancer ele-
ments, an RBEIII site and an upstream USF site (Fig. 
2A) (reviewed in [41]). Importantly, the extensive 
HIV-1 polymorphism detected in vivo, extends to the 
LTR ([15, 42] and references therein).   
  In particular, a length polymorphism immedi-
ately 5’ of the enhancer region, has been detected, in-
vestigated, or referred to by a growing list of publica-
tions [42-60]. This polymorphism was initially de-
tected as a 24 base pair duplication by Golub, Li and 
Volsky, looking for LTR variants; but no regulatory 
cis-acting motifs were described within it, despite a 
correlation with increased transcription [43]. Blum-
berg and co-authors, described a similar duplication, 
in adult and pediatric patients, while looking for 
variant nef sequences, but again did not find any mo-
tifs that might explain functional significance [44]. 
Koken and co-authors, were the first to refer to this 
duplication as the “CTG”-motif, and noted that it en-
compassed a repeat of the sequence 5’-ACTGCTGA-3’, 
and further found that a single “CTG”-motif virus, 
could out-compete an isogenic virus containing the 
duplication, in co-culture experiments, in 42 days [45]. 
These authors also noted similarities between the du-
plicated region and the recently-described TCF-1α 
(hLEF) binding site, and pointed out that HIVANT 70, 
as well as SIVCPZ, have the duplicated “CTG”-motif 
([45] and references therein). These authors also 
pointed out that Nakanishi, Masamune and Kobaya-
shi, had described the “CTG”-motif region as a novel 
cis-acting, cell-specific element [61]. In fact, in their 
paper, Nakanishi and co-authors designated this re-
gion (-157 to -121) the Upstream Regulatory Element 
(URE) and showed that it bound a transcription factor 
(designated URE-binding factors C1 and C2, by 
EMSA-specific analysis with nuclear extracts) distinct 
from AP-1 [61]. Furthermore, Koken and co-authors 
[45] noted that Zeichner, Kim and Alwine, had pub-
lished data suggesting positive regulation in the 
“CTG”-motif region [62]. Soon afterwards, Kim, Gon-
zales, Zeichner and Alwine, published another paper, 
showing a more profound effect of mutations in the 
URE-region (“CTG”-motif), in the context of chroma-
tin and viral replication, but attributed the effect to 
mutation of the TCF-1α (hLEF) binding-site [63]. In 
another paper by Koken and co-authors, they ex-
tended their initial finding, first showing that 
“CTG”-motif deleted, and “CTG”-motif duplicated 
isogenic viruses, are out-competed in cell culture as-
says by the monomeric isomeric virus [46]. These au-
thors also showed that a Circa 64kD protein, binds 
with specificity to the 5’-ACTGCTGA-3’ sequence, 
duplicated in the “CTG”-motif duplications and ob-
tained similar EMSA results to those of Nakanishi and 
co-authors, but further reported no correlation be-
tween the “CTG”-motif duplication and disease stage 
or viral phenotype [46, 61]. So, by 1994, it was already 
clear that a cis-element, named URE, enhanced viral 
replication, contained a putative binding site for 
TCF-1α (hLEF), could specifically bind proteins from 
nuclear extracts, and was encompassed in a frequent 
Nef/LTR duplication (“CTG”-motif duplication). 
Furthermore it was clear that whatever the in vivo 
function of the “CTG”-motif duplication, in tissue 
culture assays with isogenic viruses, no dramatic ef-
fects were observed.   
 Further reports on this region of the HIV-1 LTR, 
included a paper from Michael and co-authors, that 
detected the TCF-1α duplication in uncultured sam-
ples from patients, and suggested it may mediate a 
repressive effect [47], and a paper by Ait-Khaled, also 
detecting the TCF-1α duplication, in post-mortem 
samples [48]. However, in 1996, in a cross-sectional 
analysis of nearly 500 HIV-1 LTRs, we published that 
the “CTG”-motif or URE region duplications, could 
best be aligned as a single larger polymorphism, 
which we named the most frequent natu-
rally-occurring length polymorphism (MFNLP) of the 
HIV-1 LTR [42].  Int. J. Biol. Sci. 2007, 3 
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Figure 1. The MFNLP is generated during reverse transcription. (A) Synthesis of minus strong stop DNA, begins with t-RNA 
(clover-leaf structure) binding to the primer binding site (pbs), followed by RNA-templated polymerization of minus strong stop 
DNA (dashed arrow). RNase H degrades the template RNA after polymerization (arrows); (B) Template switching to the other 
RNA genome copy or to the same RNA, occurs via complementary sequences in the Repeat region (R). During the template 
switch, slippage can occur; (C) Minus strand extension could combine with slippage, templated and non-templated polymerization, 
resulting in duplication of the URE/RBEIII/partial E-box region (single white box, in RNA U3 region), generating a first copy of 
the MFNLP (two white boxes in U3 region), in the minus DNA. RNAse H continues to degrade the RNA genome, leaving just the 
polypurine tracts. (D) Initial synthesis of plus strand DNA begins from the central polypurine tract (cppt) and from the 
3’-polypurine tract (3’-ppt), resulting in synthesis of a plus strand MFNLP (four white boxes); (E) Annealing of the free pbs, fur-
ther extension and rearrangements, are followed by nuclear import and integration of the proviral HIV-1 sequences. (F) The final 
integrated proviral sequences contain a 5’-LTR and a 3’-LTR with U3, R, U5 sequences. In this model, both the 5’ and 3’-LTR 
would contain the MFNLP. Note the Nef ORF in the 3’-LTR and the Nef/LTR sequences in the 5’-LTR. Integrity of the Nef TGA 
stop codon (ACTGCTGA) is critical for RBF-2 binding to the MFNLP. Int. J. Biol. Sci. 2007, 3 
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Furthermore, we proposed that the MFNLP en-
compassed a binding site for an unpublished nuclear 
factor named RBF-2, instead of TCF-1α [42]. This 
transcription factor was defined in a subsequent pub-
lication [64], by a TGA-specificity for the 
5’-ACTGCTGA-3’ sequence, in crude nuclear extracts, 
and correlated with a region of the HIV-1 LTR re-
quired for optimal responsiveness to Ras signaling 
through the MAPK pathway, in tissue culture tran-
sient transfections. This sequence was named the Ras- 
responsive binding element III (RBEIII) [64]. Strikingly, 
a subsequent publication by Linqi Zhang and 
co-authors, reported a TCF-1α duplication in a patient 
that progressed towards AIDS, despite the lack of 
NFκB binding [49]. Interestingly, these authors sug-
gested a compensatory role for the TCF-1α duplication, 
in the face of NFκB binding-site abrogation, yet they 
found very little effect of the duplication in tissue cul-
ture [49]. Soon after, Kirchhoff and co-authors, re-
ported on the presence of the MFNLP sequence in 
clinical samples, but did not point out that they du-
plicated RBEIII sequences, responsive to Ras [50]. 
Similarly, Zhang and co-authors, reported on more 
clinical samples with TCF-1α duplications, for which 
they found no phenotype, but failed to point out that 
the MFNLPs duplicated RBEIII [51]. Quinones-Mateu, 
reported similar detection of sequence duplications, 
which we called MFNLPs [53]. In 1998, we further ex-
panded our knowledge about the RBEIII and 
MFNLP-binding proteins, by showing: (i) that hLEF 
(TCF-1α) can footprint on the wild type site but not on 
all MFNLPs or RBEIII sites; (ii) that all MFNLPs bind 
RBF-2; and (iii) that a small repressive effect was me-
diated through the MFNLP in transient transfections 
[65]. In 1999 Naghavi and co-authors also reported 
TCF-1α duplications in clinical samples [55, 66]. At 
this time, we had already attempted to purify the 
components of RBF-2 by chromatography, including 
an oligo-affinity step [67]. Purified RBF-2 included 
proteins of approximately 120 kD and 45kD, however 
our repeated attempts to obtain peptide sequences 
from large scale purifications were inconclusive [67].   
  Importantly, in the lab of Robert Roeder, Na-
ghavi and I began doing some experiments to confirm 
her sequencing data that predicted various HIV-1 
subtypes would not bind to the NRE USF site, since 
the sequence was not highly conserved, as I had 
shown for samples from the long-standing Vancouver 
Lymphadenopathy Study (VLAS) cohort [42]. While 
studying the role of USF-1 in HIV-1 LTR-directed 
transcription and viral replication, we used a double 
stranded RBEIII site and a mutant RBEIII site, as a 
non-specific competitor in an EMSA with labeled 
double stranded E-box targets, encompassing the up-
stream USF-1 site in the prototypical LAV HIV-1 LTR 
sequence, and nuclear extracts (NRE B USF site, Fig 2B, 
lane1). Surprisingly, we found that at 100X molar ex-
cess, RBEIII competed with the band shift, but the 
RBEIII mutant did not (Fig 2B, lane 9 versus lane 10). 
Although we at first assumed we had made a mistake, 
we immediately tested our new hypothesis that RBF2 
contains USF-1, by competing a standard nuclear ex-
tract RBF2-RBEIII EMSA, with the E-box unlabelled 
target (Fig. 2C, lane 2). The hallmark of the RBF2 
EMSA (Fig 2C, lane 1) is competition with 100X wild 
type RBEIII (Fig. 2C, lane 5) in the face of no competi-
tion with 100X mutant RBEIII (Fig. 2C, lane 4). The 
specific RBF2 bands were further tested with the 
non-specific 100X wtNFκB sequences from the proto-
type LAV HIV-1 LTR (Fig. 2C, lane 3). This important 
result indicated that our initial observation was true, 
and suggested that RBF2 contains USF-1. We therefore 
compared the EMSA mobility of rUSF-1 versus nu-
clear extracts, with an RBEIII target (Fig. 2D). The 
standard RBF-2 EMSA (Fig. 2D, lanes 1-4, lower arrow) 
appears to have a specific band that is lower in mobil-
ity than the specific band forming with rUSF-1 (Fig. 
2D, lanes 5-10). Importantly, although the mobility is 
slightly different, both bands are specific, since the 
nuclear extract band can be competed with 100X mo-
lar excess of wtRBEIII (lane 2) but not with 100X mut 
RBEIII (lane 3) and the rUSF-1 band can be competed 
with 100X wtRBEIII (lane 8) but not 100X mutRBEIII 
(lane 9). Additionally, antibodies to rUSF-1 appear to 
supershift both RBF-2 and rUSF-1 (lanes 4 and 10), 
consistent with USF-1 being in RBF-2. Since our focus 
is on the MFNLP and MFNLPs encompass RBEIII se-
quences, the above results strongly suggested that 
MFNLPs would also bind USF-1. However, the ca-
nonical E-box CANNTG site, recognized by USF-1, is 
not present in RBEIII sites. Indeed Target Detection 
Analysis (TDA), with random targets, using USF-1, 
does not select an RBEIII site [68]. However, we noted 
that in the purified RBF-2 preparations there was a 
circa 120 kD component [67]. It was then Robert 
Roeder who immediately suggested to me that RBF-2 
was comprised of USF and TFII-I. Because TFIIi and 
USF-1 bind the initiator/E-box region of the HIV-1 
LTR, and RBF-2 had been shown to bind an RBEI site 
(in addition to the RBEIII site) that overlaps with the 
initiator sequences (Fig.2A) [64], the hypothesis that 
RBF-2 was comprised of USF and TFII-I seemed plau-
sible. In fact, I found this was indeed the case, for at 
least 2 naturally occurring RBEIII HIV-1 LTR se-
quences (from clones pMCE36.1 and pMCE9.104, de-
scribed elsewhere [65]), one of which is encompassed 
in an MFNLP (pMCE9.104) (Fig. 2D), in addition to 
the prototype HIV-1 LTR LAV sequences (above). 
Importantly, since binding of rUSF-1 alone (Fig. 2D, 
lanes 1 and 2) and binding of rTFIIi alone (lanes 5 and 
6) is significantly weaker than when USF-1 is com-
bined with TFIIi (lanes 3 and 4), it is likely that coop-
erative binding was occurring. Indeed, this important 
result suggested that USF-1 and TFIIi, when inte-
grated at an RBEIII site, exert a stronger effect than 
individually, thus potentially explaining why their 
individual binding to an RBEIII site has not been pre-
viously observed.   Int. J. Biol. Sci. 2007, 3 
 
322
 
Figure 2. MFNLPs and RBEIII, bind USF-1 and TFIIi. (A) Schematic representation of the HIV-1 LTR. Some transcription 
factors landmarks (NFAT, USF-1, RBF2, NFkB, SP-1) known to interact with target sequences on the HIV-1 LTR are indicated in 
their relative positions. The -121 position where the MFNLPs occur is indicated, with the MFNLP above, bound by RBF2 at the 
MFNLP RBEIII site. The -453 and +185 sites indicate the extremes of the LTR. The +1 site indicates the start of transcription and 
the +98 site, the end of Tar sequences. The dashed circles represent the approximate positions of two nucleosomes (Nuc-0 and 
Nuc-1). (B) RBEIII sequences specifically compete with a USF EMSA. The dsNREB oligosed as targets for the respective Hela 
nuclear extracts. Inclusion of competitor DNA sequences is indicated by a plus sign. (C) A USF-1 site competes specifically with 
RBF2 for an RBEIII site. A p32-labelled wt RBEIII ds oligo was used as target in EMSA with nuclear extracts from HeLa-s cells 
(NE, lanes 1-5). The target site that the respective competitor ds oligo sequences encompass, are designated with a + sign above 
each lane, and are listed on the right top of the panel. (D) rUSF-1 specifically binds to RBEIII, but results in a higher mobility 
EMSA than RBF2. A p32-labelled wt RBEIII ds oligo was used as target in EMSA with nuclear extracts from HeLa-s cells (NE, 
lanes 1-4) or with rUSF-1 (lanes 5-10). The target site that the respective competitor ds oligo sequences encompass, are designated 
with a + sign above each lane, and are listed on the right top of the panel. Lower arrow: NE-RBEIII (RBF2) complex. Upper arrow: 
rUSF-1-RBEIII complex. (D) rTFIIi and rUSF-1 bind cooperatively to MFNLP and wt RBEIII sites from 2 patients. A 
p32-labelled ds oligonucleotide target, encompassing the RBEIII site of either clone pMCE36.1 (lanes 1, 3, 5) or pMCE9.104 
(lanes 2, 4, 6) was used as target in EMSA with either rUSF-1, TFIIi, or both, as indicated with a + sign above each lane, and 
listed at the right top of the panel. Lower arrow: Free pMCE36.1 ds oligonucleotide. Upper arrow: Free pMCE9.104 ds oligonu-
cleotide. (B to E) The NRE, RBEIII, USF, NFκB sequences and EMSA conditions have been previously described [55, 64, 65, 67, 
69]. Int. J. Biol. Sci. 2007, 3 
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 Subsequent to our discovery, we asked the labo-
ratory of Ivan Sadowski to confirm our results. Martin 
Hirst detected both USF and TFII-I in RBF-2 purifica-
tions [67], confirming our results. All the above initial 
findings were excluded from our publication about 
the NRE USF subtype sites [69], in order to better de-
velop them into a clearer picture of the function of 
USF/TFII-I at the RBEIII sites, in collaboration with 
the lab of Ivan Sadowski (see below) [70]. 
 Importantly, Jeeninga and co-authors, confirmed 
in 2000, that RBEIII sites are absolutely conserved, in 
LTR subtypes A through G [66]. A publication in 2000 
by Gomez-Roman and co-authors, detected MFNLP 
sequences, duplicating RBEIII, in a long term non 
progressor (LTNP), but no deletions to RBEIII sites 
were found [56]. These LTNP are clinically distinct 
groups with lower viral replication and a slower or 
non-progressive form of HIV-1 infection (see below). 
  In 2000, Chen and co-authors found that an 
MFNLP from one of their patient samples, created a 
new AP-1 binding site, and identified c-Fos and JunB 
as binding proteins for their MFNLP [57]. Birch and 
co-authors described in 2001, LTNP from the Sydney 
Blood Bank Cohort (SBBC), that are accumulating 
progressively more LTR/Nef deletions, and some of 
these persons harbor RBEIII duplications in the form 
of MFNLPs [58]. Similarly, another LTNP study ap-
pears to have LTR/Nef sequences progressively ac-
cumulating greater deletions over time [60]. However 
it has not been at all clear if the LTR or the Nef dele-
tions are responsible for the LTNP phenotype. 
 In 2002, Hiebenthal-Millow and Kirchhoff, found 
that in primary T cells, the MFNLP appears not to 
confer a major effect upon viral replication in culture 
[59]. A noteworthy observation about this paper is 
that these authors actually found enhanced transcrip-
tional activity occurred when both the RBEIII site and 
MFNLPs were deleted, and that the MFNLP slightly 
reduced transcriptional activity.   
 Perhaps the most important paper about the role 
of the RBEIII site and the MFNLP is that from Chen 
and co-authors [70]. This paper expands on our initial 
discovery that RBF-2 is composed of TFIIi and USF, 
based on the TGA specificity of the EMSA used by 
Bell and Sadowski [64]. RBF-2 appears to be a het-
erodimer of USF-1/USF-2; and TFII-I appears to load 
USF-1/ USF-2 onto the RBEIII site. Importantly, this 
paper shows that RBEIII mutant LTRs are unrespon-
sive to cross-linking of the T cell receptor or stimula-
tion with PMA and ionomycin. Thus it appears that 
the phenotype of the RBEIII site and hence the com-
pensatory MFNLP role, is to provide a target for 
Ras/MAPK activation of the HIV-1 LTR, in the con-
text of chromatin [70, 71].   
3.  Nef, LTNP and RBF-2 
Importantly, the most recent SBBC LTNP study, 
indicates that there is a convergence in LTR/Nef dele-
tions for these LTNPs [72]. These deletions appear to 
leave the sequences downstream of the NFκB sites 
intact, yet appear to be abrogating RBEIII sites, since 
they are deleted, without MFNLPs. Importantly, there 
are publications indicating that Nef can activate the 
MAPK pathway [73] and increase T cell activation [74]. 
Therefore Nef could be actually acting through the 
Nef/LTR cis-acting RBEIII site, which is abrogated in 
the SSBC LTNPs [72]. I therefore propose the model in 
figure 3. LTRs with normal RBEIII sites and a normal 
Nef sequence, could contribute to high viral replica-
tion and progress to AIDS (Fig 3A). The presence of 
MFNLPs in the context of normal RBEIII sites would 
simply provide a failsafe function. However, LTRs 
with mutated RBEIII site would require an MFNLP, as 
a compensatory mechanism (Fig 3 B). If however, 
LTRs receive difficult-to-revert Nef deletions, either 
after an RBEIII mutation (Fig. 3C) or prior to an RBEIII 
mutation (Fig. 3D), then the selective pressure to 
maintain the RBEIII site and the MFNLP disappears. 
The result of this model, would explain the conver-
gent deletions observed in the LTR/Nef SSBC LTNP 
study, as well as being consistent with the role for 
RBF-2, RBEIII and MFNLPs. 
  Whether my model about LTNP is true or not, 
the conserved nature of the RBEIII sites in vivo, makes 
it an important potential target for delivery of chi-
meric transcription factor repressors, which could 
emulate the LTNP phenotype, by blocking activation 
through this highly conserved site [75]. This is illus-
trated in Figure 4, where a chimeric transcription fac-
tor encompassing a repressor (such as MCEF[75, 76]) 
and a DNA binding partner (RBF-2), might have the 
potential to both block tat-transactivation and inter-
fere with the function of RBEIII. 
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Figure 3. MFNLPs compensate for RBEIII mutations, by maintaining functional coupling, of Nef and RBF-2. In this sche-
matic representation four states are considered. In A & B, normal progressive disease with high viral titer would develop. In C & 
D, difficult-to-revert-mutations to Nef or the RBEIII site, would result in LTNP, and deletions of both RBEIII LTR sequences and 
Nef sequences. This is because, in our model, Nef can activate the MAPK pathway, and exert its effects through RBEIII. 
 Int. J. Biol. Sci. 2007, 3 
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Figure 4. Chimeric Transcription Factor Repression (CTFR) of HIV-1. Delivery of a repressor with the ability to interfere 
with Tat-transactivation and bind to the RBEIII/ MFNLP is hypothesized. The HIV-1 LTR is drawn with some salient transcrip-
tion factors indicated. The RNA stem-loop structure termed TAR, can form a ternary complex with HIV-1 TA and P-TEFb, to 
hyperphosphorylate the carboxy terminal domain (CTD) of RNA Polymerase II (PolII). Because MCEF interacts with P-TEFb and 
represses HIV-1 Tat-transactivation, if tethered to the RBEIII/ MFNLP site, MCEF could interfere with the binding of RBF-2 (3) 
and tat transactivation (1 and 2). 
 
References 
1.   Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, 
Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, 
Rozenbaum W, and Montagnier L. Isolation of a T-lymphotropic 
retrovirus from a patient at risk for acquired immune deficiency 
syndrome (AIDS). Science 1983; 220: 868-871 
2.   Wattel E, Vartanian JP, Pannetier C, and Wain-Hobson S. Clonal 
expansion of human T-cell leukemia virus type I-infected cells in 
asymptomatic and symptomatic carriers without malignancy. J 
Virol 1995; 69: 2863-2868 
3.  Gessain A, Gallo RC, and Franchini G. Low degree of human 
T-cell leukemia/lymphoma virus type I genetic drift in vivo as a 
means of monitoring viral transmission and movement of an-
cient human populations. J Virol 1992; 66: 2288-2295 
4.  Wain-Hobson S. Running the gamut of retroviral variation. 
Trends Microbiol 1996; 4: 135-141 
5.   Komurian F, Pelloquin F, and de The G. In vivo genomic vari-
ability of human T-cell leukemia virus type I depends more 
upon geography than upon pathologies. J Virol 1991; 65: 
3770-3778 
6.  Kunkel TA. DNA replication fidelity. J Biol Chem 1992; 267: 
18251-18254 
7.   Preston BD, and Dougherty JP. Mechanisms of retroviral muta-
tion. Trends Microbiol 1996; 4: 16-21 
8.  Zenkin N, Yuzenkova Y, and Severinov K. Transcript-assisted 
transcriptional proofreading. Science 2006; 313: 518-520 
9.  Freed EO. HIV-1 replication. Somat Cell Mol Genet 2001; 26: 
13-33 
10. Rausch JW, and Le Grice SF. 'Binding, bending and bonding': 
polypurine tract-primed initiation of plus-strand DNA synthesis 
in human immunodeficiency virus. Int J Biochem Cell Biol 2004; 
36: 1752-1766 
11. Cheynier R, Gratton S, Vartanian JP, Meyerhans A, and 
Wain-Hobson S. G --> A hypermutation does not result from 
polymerase chain reaction. AIDS Res Hum Retroviruses 1997; 13: 
985-986 
12. Meyerhans A, Vartanian JP, Hultgren C, Plikat U, Karlsson A, 
Wang L, Eriksson S, and Wain-Hobson S. Restriction and en-
hancement of human immunodeficiency virus type 1 replication 
by modulation of intracellular deoxynucleoside triphosphate 
pools. J Virol 1994; 68: 535-540 
13. Vartanian JP, Plikat U, Henry M, Mahieux R, Guillemot L, Mey-
erhans A, and Wain-Hobson S. HIV genetic variation is directed 
and restricted by DNA precursor availability. J Mol Biol 1997; 
270: 139-151 
14. Vartanian JP, Meyerhans A, Sala M, and Wain-Hobson S. G-->A 
hypermutation of the human immunodeficiency virus type 1 
genome: evidence for dCTP pool imbalance during reverse 
transcription. Proc Natl Acad Sci U S A 1994; 91: 3092-3096 
15. Delassus S, Cheynier R, and Wain-Hobson S. Evolution of human 
immunodeficiency virus type 1 nef and long terminal repeat 
sequences over 4 years in vivo and in vitro. J Virol 1991; 65: 
225-231 
1 6 .  G o o d e n o w  M ,  H u e t  T ,  S a u r i n  W ,  K w o k  S ,  S n i n s k y  J ,  a n d  
Wain-Hobson S. HIV-1 isolates are rapidly evolving quasispe-
cies: evidence for viral mixtures and preferred nucleotide sub-
stitutions. J Acquir Immune Defic Syndr 1989; 2: 344-352 
17. Vartanian JP, Meyerhans A, Asjo B, and Wain-Hobson S. Selec-
tion, recombination, and G----A hypermutation of human im-
munodeficiency virus type 1 genomes. J Virol 1991; 65: 1779-1788 
18. Skalka A, and Goff S. Reverse Transcriptase. New York: Cold 
Spring Harbor Press. 1993 
19. Vartanian JP, Sommer P, and Wain-Hobson S. Death and the 
retrovirus. Trends Mol Med 2003; 9: 409-413 
20. Suspene R, Rusniok C, Vartanian JP, and Wain-Hobson S. Twin 
gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics 
of lentiviral replication. Nucleic Acids Res 2006; 34: 4677-4684 
21. Simon V, Zennou V, Murray D, Huang Y, Ho DD, and Bieniasz 
PD. Natural variation in Vif: differential impact on 
APOBEC3G/3F and a potential role in HIV-1 diversification. 
PLoS Pathog 2005; 1: e6 
22. Patel PH, and Preston BD. Marked infidelity of human immu-
nodeficiency virus type 1 reverse transcriptase at RNA and DNA 
template ends. Proc Natl Acad Sci U S A 1994; 91: 549-553 
23. Allain B, Lapadat-Tapolsky M, Berlioz C, and Darlix JL. Transac-
tivation of the minus-strand DNA transfer by nucleocapsid 
protein during reverse transcription of the retroviral genome. 
Embo J 1994; 13: 973-981 
24. Darlix JL, Vincent A, Gabus C, de Rocquigny H, and Roques B. 
Trans-activation of the 5' to 3' viral DNA strand transfer by nu-
cleocapsid protein during reverse transcription of HIV1 RNA. C 
R Acad Sci III 1993; 316: 763-771 
25. Guo J, Henderson LE, Bess J, Kane B, and Levin JG. Human im-
munodeficiency virus type 1 nucleocapsid protein promotes ef-
ficient strand transfer and specific viral DNA synthesis by in-
hibiting TAR-dependent self-priming from minus-strand Int. J. Biol. Sci. 2007, 3 
 
326
strong-stop DNA. J Virol 1997; 71: 5178-5188 
26. Klaver B, and Berkhout B. Comparison of 5' and 3' long terminal 
repeat promoter function in human immunodeficiency virus. J 
Virol 1994; 68: 3830-3840 
27. Ramsey CA, and Panganiban AT. Replication of the retroviral 
terminal repeat sequence during in vivo reverse transcription. J 
Virol 1993; 67: 4114-4121 
28. Temin HM. Retrovirus variation and reverse transcription: ab-
normal strand transfers result in retrovirus genetic variation. 
Proc Natl Acad Sci U S A 1993; 90: 6900-6903 
29. Panganiban AT, and Fiore D. Ordered interstrand and in-
trastrand DNA transfer during reverse transcription. Science 
1988; 241: 1064-1069 
30. Jones JS, Allan RW, and Temin HM. One retroviral RNA is suffi-
cient for synthesis of viral DNA. J Virol 1994; 68: 207-216 
31. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, 
Fultz PN, Girard M, Shaw GM, Hahn BH, and Sharp PM. The 
heterosexual human immunodeficiency virus type 1 epidemic in 
Thailand is caused by an intersubtype (A/E) recombinant of 
African origin. J Virol 1996; 70: 7013-7029 
32. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, 
Meese E, Wain-Hobson S, and Meyerhans A. Multiply infected 
spleen cells in HIV patients. Nature 2002; 418: 144 
33. Meyerhans A, Jung A, Maier R, Vartanian JP, Bocharov G, and 
Wain-Hobson S. The non-clonal and transitory nature of HIV in 
vivo. Swiss Med Wkly 2003; 133: 451-454 
34. Nethe M, Berkhout B, and van der Kuyl AC. Retroviral superin-
fection resistance. Retrovirology 2005; 2: 52 
35. Preston BD. Error-prone retrotransposition: rime of the ancient 
mutators. Proc Natl Acad Sci U S A 1996; 93: 7427-7431 
36. Coffin JM. HIV population dynamics in vivo: implications for 
genetic variation, pathogenesis, and therapy. Science 1995; 267: 
483-489 
37. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and 
Markowitz M. Rapid turnover of plasma virions and CD4 lym-
phocytes in HIV-1 infection. Nature 1995; 373: 123-126 
38. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, 
Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.. Viral dy-
namics in human immunodeficiency virus type 1 infection. Na-
ture 1995; 373: 117-122 
39. Biebricher CK, and Eigen M. What is a quasispecies? Curr Top 
Microbiol Immunol 2006; 299: 1-31 
40. Wain-Hobson S, Sonigo P, Danos O, Cole S, and Alizon M. Nu-
cleotide sequence of the AIDS virus, LAV. Cell 1985; 40: 9-17 
41. Pereira LA, Bentley K, Peeters A, Churchill MJ, and Deacon NJ. A 
compilation of cellular transcription factor interactions with the 
HIV-1 LTR promoter. Nucleic Acids Res 2000; 28: 663-668 
42. Estable MC, Bell B, Merzouki A, Montaner JS, O'Shaughnessy 
MV, and Sadowski IJ. Human immunodeficiency virus type 1 
long terminal repeat variants from 42 patients representing all 
stages of infection display a wide range of sequence polymor-
phism and transcription activity. J Virol 1996; 70: 4053-4062 
43. Golub E, Li G, and Volsky D. Differences in the basal activity of 
the long terminal repeat determine different replicative capaci-
ties of two closely related human immunodeficiency virus type 1 
isolates. J Virol. 1991; 64: 3654-3660 
44. Blumberg BM, Epstein LG, Saito Y, Chen D, Sharer LR, and An-
and R. Human immunodeficiency virus type 1 nef quasispecies 
in pathological tissue. J Virol 1992; 66: 5256-5264 
45. Koken SE, van Wamel JL, Goudsmit J, Berkhout B, and Geelen JL. 
Natural variants of the HIV-1 long terminal repeat: analysis of 
promoters with duplicated DNA regulatory motifs. Virology 
1992; 191: 968-972 
46. Koken SE, van Wamel JL, Geelen JL, and Berkhout B. Functional 
Analysis of the ACTGCTGA Sequence Motif in the Human 
I m m u n o d e f i c i e n c y  V i r u s  T y p e - 1  L o n g  T e r m i n a l  R e p e a t  P r o -
moter. J Biomed Sci 1994; 1: 83-92 
47. Michael NL, D'Arcy L, Ehrenberg PK, and Redfield RR. Naturally 
occurring genotypes of the human immunodeficiency virus type 
1 long terminal repeat display a wide range of basal and 
Tat-induced transcriptional activities. J Virol 1994; 68: 3163-3174 
48. Ait-Khaled M, McLaughlin JE, Johnson MA, and Emery VC. 
Distinct HIV-1 long terminal repeat quasispecies present in 
nervous tissues compared to that in lung, blood and lymphoid 
tissues of an AIDS patient. Aids 1995; 9: 675-683 
49. Zhang L, Huang Y, Yuan H, Chen BK, Ip J, and Ho DD. Identifi-
cation of a replication-competent pathogenic human immuno-
deficiency virus type 1 with a duplication in the TCF-1alpha re-
gion but lacking NF-kappaB binding sites. J Virol 1997; 71: 
1651-1656 
50. Kirchhoff F, Greenough TC, Hamacher M, Sullivan JL, and Des-
rosiers RC. Activity of human immunodeficiency virus type 1 
promoter/TAR regions and tat1 genes derived from individuals 
with different rates of disease progression. Virology 1997; 232: 
319-331 
51. Zhang L, Huang Y, Yuan H, Chen BK, Ip J, and Ho DD. Geno-
typic and phenotypic characterization of long terminal repeat 
sequences from long-term survivors of human immunodefi-
ciency virus type 1 infection. J Virol 1997; 71: 5608-5613 
52. Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, and 
Benedetto A. Grossly defective nef gene sequences in a human 
immunodeficiency virus type 1-seropositive long-term nonpro-
gressor. J Virol 1998; 72: 3646-3657 
53. Quinones-Mateu ME, Mas A, Lain de Lera T, Soriano V, Alcami J, 
Lederman MM, and Domingo E. LTR and tat variability of 
HIV-1 isolates from patients with divergent rates of disease 
progression. Virus Res 1998; 57: 11-20 
54. Estable MC, Merzouki A, Arella M, and Sadowski IJ. Distinct 
clustering of HIV type 1 sequences derived from injection versus 
noninjection drug users in Vancouver, Canada. AIDS Res Hum 
Retroviruses 1998; 14: 917-919 
55. Naghavi MH, Schwartz S, Sonnerborg A, and Vahlne A. Long 
terminal repeat promoter/enhancer activity of different sub-
types of HIV type 1. AIDS Res Hum Retroviruses 1999; 15: 
1293-1303 
56. Gomez-Roman VR, Vazquez JA, et al. nef/long terminal repeat 
quasispecies from HIV type 1-infected Mexican patients with 
different progression patterns and their pathogenesis in 
hu-PBL-SCID mice. AIDS Res Hum Retroviruses 2000; 16: 
441-452 
57. Chen P, Flory E, Avots A, Jordan BW, Kirchhoff F, Ludwig S, and 
Rapp UR. Transactivation of naturally occurring HIV-1 long 
terminal repeats by the JNK signaling pathway. The most fre-
quent naturally occurring length polymorphism sequence in-
troduces a novel binding site for AP-1 factors. J Biol Chem 2000; 
275: 20382-20390 
58. Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, Sak-
sena N, Cunningham AL, Mills J, and Sullivan JS. An examina-
tion of signs of disease progression in survivors of the Sydney 
Blood Bank Cohort (SBBC). J Clin Virol 2001; 22: 263-270 
59. Hiebenthal-Millow K, and Kirchhoff F. The most frequent natu-
rally occurring length polymorphism in the HIV-1 LTR has little 
effect on proviral transcription and viral replication. Virology 
2002; 292: 169-175 
60. Kondo M, Shima T, Nishizawa M, Sudo K, Iwamuro S, Okabe T, 
Takebe Y, and Imai M. Identification of attenuated variants of 
HIV-1 circulating recombinant form 01_AE that are associated 
with slow disease progression due to gross genetic alterations in 
the nef/long terminal repeat sequences. J Infect Dis 2005; 192: 
56-61 
61. Nakanishi Y, Masamune Y, and Kobayashi N. A novel cis-acting 
element that controls transcription of human immunodeficiency 
virus type 1 DNA, depending on cell type. J Virol 1991; 65: 
6334-6338 Int. J. Biol. Sci. 2007, 3 
 
327
62. Zeichner SL, Kim JY, and Alwine JC. Linker-scanning mutational 
analysis of the transcriptional activity of the human immunode-
ficiency virus type 1 long terminal repeat. J Virol 1991; 65: 
2436-2444 
63. Kim JY, Gonzalez-Scarano F, Zeichner SL, and Alwine JC. Rep-
lication of type 1 human immunodeficiency viruses containing 
linker substitution mutations in the -201 to -130 region of the 
long terminal repeat. J Virol 1993; 67: 1658-1662 
64. Bell B, and Sadowski I. Ras-responsiveness of the HIV-1 LTR 
requires RBF-1 and RBF-2 binding sites. Oncogene 1996; 13: 
2687-2697 
65. Estable MC, Bell B, Hirst M, and Sadowski I. Naturally occurring 
human immunodeficiency virus type 1 long terminal repeats 
have a frequently observed duplication that binds RBF-2 and 
represses transcription. J Virol 1998; 72: 6465-6474 
66. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, 
Verhoef K, and Berkhout B. Functional differences between the 
long terminal repeat transcriptional promoters of human im-
munodeficiency virus type 1 subtypes A through G. J Virol 2000; 
74: 3740-3751 
67. Estable MC, Hirst M, Bell B, O'Shaughnessy MV, and Sadowski I. 
Purification of RBF-2, a transcription factor with specificity for 
the most conserved cis-element of naturally occurring HIV-1 
LTRs. J Biomed Sci 1999; 6: 320-332 
68. Bendall AJ, and Molloy PL. Base preferences for DNA binding by 
the bHLH-Zip protein USF: effects of MgCl2 on specificity and 
comparison with binding of Myc family members. Nucleic Acids 
Res 1994; 22: 2801-2810 
69. Naghavi MH, Estable MC, Schwartz S, Roeder RG, and Vahlne A. 
Upstream stimulating factor affects human immunodeficiency 
virus type 1 (HIV-1) long terminal repeat-directed transcription 
in a cell-specific manner, independently of the HIV-1 subtype 
and the core-negative regulatory element. J Gen Virol 2001; 82: 
547-559 
70. Chen J, Malcolm T, Estable MC, Roeder RG, and Sadowski I. 
TFII-I regulates induction of chromosomally integrated human 
immunodeficiency virus type 1 long terminal repeat in coopera-
tion with USF. J Virol 2005; 79: 4396-4406 
71. Sadowski I, and Mitchell DA. TFII-I and USF (RBF-2) regulate 
Ras/MAPK-responsive HIV-1 transcription in T cells. Eur J 
Cancer 2005; 41: 2528-2536 
72. Churchill MJ, Rhodes DI, Learmont JC, Sullivan JS, Wesselingh 
SL, Cooke IR, Deacon NJ, and Gorry PR. Longitudinal analysis 
of human immunodeficiency virus type 1 nef/long terminal re-
peat sequences in a cohort of long-term survivors infected from a 
single source. J Virol 2006; 80: 1047-1052 
73. Schrager JA, Der Minassian V, and Marsh JW. HIV Nef increases 
T cell ERK MAP kinase activity. J Biol Chem 2002; 277: 6137-6142 
74. Schrager JA, and Marsh JW. HIV-1 Nef increases T cell activation 
in a stimulus-dependent manner. Proc Natl Acad Sci U S A 1999; 
96: 8167-8172 
75. Niedzielski MF, Hopewell R, Ismail Z, and Estable MC. MCEF is 
localized to the nucleus by protein sequences encoded within 
three distinct exons, where it represses HIV-1 Tat-transactivation 
of LTR-directed transcription. Int J Biol Sci 2007; 3: 225-236 
76. Estable MC, Naghavi MH, Kato H, Xiao H, Qin J, Vahlne A, and 
Roeder RG. MCEF, the newest member of the AF4 family of 
transcription factors involved in leukemia, is a positive tran-
scription elongation factor-b-associated protein. J Biomed Sci 
2002; 9: 234-245 